| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC9309 | AZD-0156 Featured | AZD-0156 is an orally bioavailable ataxia telangiectasia mutated (ATM) kinase inhibitor, with potential chemo-/radio-sensitizing and antineoplastic activities. |
|
| DC20002 | AZD-0284 Featured | AZD0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders. |
|
| DC11481 | AZD-0364 Featured | AZD-0364 is a potent and selective ERK2 inhibitor extracted from patent WO2017080979A1, compound example 18, has an IC50 of 0.6 nM. |
|
| DC20718 | AZD-0837 | AZD-0837 is a novel oral anticoagulant that after bioconversion to its active form is a potent and reversible thrombin inhibitor, has been investigated in phase II studies for prevention of stroke and systemic embolic events in patients with atrial fibril |
|
| DC23670 | AZD-1092 | AZD-1092 (GKA-80) is a potent Glucokinase (GK) activator with EC50 of 30 nM. |
|
| DC20719 | AZD-1305 | AZD-1305 is a novel antiarrhythmic agent that predominantly blocks the rapid component of IKr, the L-type calcium current, and the inward sodium current in mammalian cells and ventricular cardiomyocytes. |
|
| DC7073 | AZD2014 | AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM; highly selective against multiple PI3K isoforms (α/β/γ/δ). |
|
| DC7748 | AZD-26(AKT-IN-1） Featured | AZD-26 is an inhibitor of AKT. AZD-26 inhibits the phosphorylation of Thr308 on AKT in BT474 cells with an IC50 of 422 nM. |
|
| DC11847 | AZD2716 | AZD2716(AZD-2716) is a novel potent, selective, orally bioavailable sPLA2 inhibitor with excellent plasma sPLA2 inhibition (IC50=0.1 nM). |
|
| DC20050 | AZD2906 | AZD2906 is a selective glucocorticoid receptor (GR) agonist, with IC50s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blood, respectively. AZD2906 increases micronucleated immature erythrocytes (MIE) in the bone marrow of rats |
|
| DC20724 | AZD-3161 | AZD-3161 is a potent and selective sodium channel Nav1.7 blocker for treatment of nociceptive pain. . |
|
| DC12265 | AZD3229 Tosylate | AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. |
|
| DC9946 | Lanabecestat(AZD3293,LY-3314814) | AZD3293 is a potent and selective orally active, brain-permeable BACE1 inhibitor,currently in development as a potential treatment for early Alzheimer’s disease. |
|
| DC5013 | AZD3514 | AZD3514 is a potent and oral androgen receptor with Ki of 2.2 μM and has ability of reducing AR protein expression. |
|
| DC8060 | AZD-3988 | AZD-3988 is a potent and selective diacylglycerol acyltransferase (DGAT-1) inhibitor (IC50 = 0.6 nM). |
|
| DC20725 | AZD 4017 | AZD4017 is a potent, selective, and orally bioavailable human 11β-HSD1 with IC50 of 7 nM, shows no significant activity against 11β-HSD1 and 17β-HSD1, 17β-HSD3 (IC50>30 uM). |
|
| DC23282 | AZD 4320 | AZD4320 is a BH3 mimetic and dual Bcl-2/Bcl-XL inhibitor with IC50 of <1 nM. |
|
| DC11295 | AZD-4573 | AZD4573 is a CDK9 inhibitor with an IC50 of <3 nM extracted from patent US 20160376287 A1, example 14. |
|
| DC23436 | AZD-4818 | AZD-4818 is a highly potent, selective CCR1 antagonist with pIC50 of 8.6, inhibits chemotaxia of human monocytes to MIP-1α in a concentration-dependent manner. |
|
| DC10773 | AZD5069 Featured | AZD-5069 is a potent and selective CXCR2 antagonist with the potential to inhibit neutrophil migration into the airways in patients with COPD. |
|
| DC10288 | AZD5153 6-Hydroxy-2-naphthoic acid Featured | AZD5153 6-Hydroxy-2-naphthoic acid is the 6-Hydroxy-2-naphthoic acid of AZD5153. AZD5153 is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor; disrupts BRD4 with an IC50 of 1.7 nM. |
|
| DC10774 | AZD5153 Featured | AZD5153 is a potent bivalent triazolopyridazine based Bromodomain and Extraterminal (BET) Inhibitor. |
|
| DC20727 | AZD-5248 | AZD-5248 is a potent, selective, first generation, oral inhibitor of dipeptidyl peptidase 1 (DPP1).. |
|
| DC20716 | AZD5576 | AZD5576(AZD 5576) is a potent, highly selective, and orally bioavailable inhibitor of CDK9 with IC50 of < 5 nM, decreases phosphorylation of Ser2-RNAPII in cells with an IC50 of 96 nM. |
|
| DC7075 | AZD-5597 | AZD-5597 is potent CDK inhibitor with in vitro anti-proliferative effects against a range of cancer cell lines. |
|
| DC22009 | AZD5718 Featured | AZD5718 (AZD-5718, AZD 5718) is a novel potent 5-lipoxygenase activating protein (FLAP) inhibitor with binding IC50 of 6.3 nM; exhibits LTB4 inhibition in human whole blood assays with IC50 of 39 nM; reduce the production of pro-inflammatory and vasoactive leukotrienes both in vitro and in vivo. |
|
| DC20728 | AZD-5718 | AZD-5718 is an orally available small molecule, 5-lipoxygenase activating protein (FLAP) inhibitor.. |
|
| DC22007 | AZD5904 | AZD5904 (AZD-5904) is a potent, selective irreversible, orally bioavailable myeloperoxidase (MPO) inhibitor with IC50 of 140 nM, similar potency in mouse and rat. |
|
| DC12553 | AZD6088 | AZD6088 (AZD-6088) is a potent and selective, orally bioavailable partial agonist of the M1 muscarinic receptor, reduces heat hyperalgesia in SNL rats with an EC50 of 46.6 nM.. |
|
| DC20731 | AZD-7325 Featured | AZD-7325 is a potent, α2/3 functionally selective, partial GABAA receptor modulator with pKi of 9.51. |
|
